Physician profile
Meredith Ray
NPI 1497723944
$1,153.76
in general payments reported to CMS, 2019-2025
17 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $58.64 · 2022: $73.61 · 2023: $172 · 2024: $311 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $228.69 | 2020-2025 | Farxiga, Airsupra |
| Pfizer INC. | $167.11 | 2019-2025 | |
| Exact Sciences Corporation | $140.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $136.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $77.61 | 2025 | Spravato |
| Glaxosmithkline, LLC. | $73.78 | 2022-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $72.04 | 2019-2025 | |
| Amgen INC. | $56.01 | 2019-2025 | Repatha |
| Optinose US, INC. | $43.79 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $29.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.76 | 2024 | Jardiance |
| Astellas Pharma US INC | $24.41 | 2024 | Veozah |
| Actelion Pharmaceuticals US, INC. | $21.48 | 2025 | Uptravi, Opsumit |
| Allergan, INC. | $17.19 | 2019 | |
| Millicent US INC | $14.54 | 2025 | Femlyv, Intrarosa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.